Initiates Phase II

Related by string. Initiate Phase II * initiates . initiate . INITIATES . INITIATE : initiates coverage . initiate impeachment proceedings . Poor Initiates Factual . Initiates Coverage / phase . phases . Phases . PHASE : Phase III clinical trials . Phase III trials . Phase III clinical . Phase 2b clinical / ii . IID . IIS . Ii : World War II . Queen Elizabeth II . Dragon Age II . Hangover Part II * *

Related by context. All words. (Click for frequent words.) 90 Completes Patient Enrollment 90 Initiates Phase III 88 Initiates Enrollment 88 Completes Enrollment 88 Initiates Clinical 88 Receives Orphan Drug Designation 88 Initiates Clinical Trial 87 Presents Positive 87 Begins Dosing 86 Initiates Phase 86 Commences Phase 86 Files IND 86 Successfully Completes Phase 85 Presents Preclinical Data 85 Presents Preclinical 85 Initiates Phase 2b 85 Submits IND 84 Meets Primary Endpoint 84 Receives Milestone Payment 84 Therapeutic Competitors Companies 84 Initiate Phase 83 Enrolls First 83 Submits Biologics License Application 83 Initiates Dosing 83 Completes Dosing 83 Receives Approvable Letter 82 Phase 2b Clinical Trial 82 Submits NDA 82 Achieves Primary Endpoint 82 Licenses Novel 82 Drug Candidate 82 Announce License Agreement 82 Reports Preclinical Data 81 Initiates Clinical Trials 81 Announces Initiation 81 Submits Response 81 BioSante Pharmaceuticals Announces 81 Granted Orphan Drug 80 Presents Positive Preclinical 80 Pivotal Phase III 80 Receives Orphan Drug 80 Novel Oral 80 Announces Poster Presentations 80 Demonstrates Significant 80 Files Investigational 80 Present Preclinical Data 80 Gets FDA Clearance 80 Patient Enrollment 80 FDA Accepts 80 Initiate Phase III 80 Receives Fast Track 80 pralatrexate injection folate analogue 79 Phase IIb Trial 79 Hsp# Inhibitor 79 Phase 2b Trial 79 Receive Milestone Payment 79 Initiate Clinical Trial 79 Announce Collaboration Agreement 79 Earns Milestone Payment 79 Therapeutic Competitors companiesandmarkets.com adEgemonye 79 Announces Tentative Approval 79 Announce Initiation 79 PRN FDA Approves 79 Phase III Clinical Trial 79 Phase IIb Clinical Trial 79 FDA Clears 79 Reveals Positive 79 Receives FDA Clearance 79 Drug Fails 79 JAK2 Inhibitor 79 Clinical Trial Results 79 Investigational Oral 79 Demonstrates Positive 79 Announces FDA Clearance 78 Commence Phase 78 Pivotal Phase 78 Phase III Pivotal 78 Combination REOLYSIN R 78 Submits Supplemental 78 Collaborators Present 78 Xcytrin R 78 R MSCRAMM 78 Sign Licensing Agreement 78 Investigational Compound 78 Oral Calcitonin 78 FOLOTYN ® 78 Receives Complete Response 78 Systemic Delivery 77 First Patient Enrolled 77 IG HCR ;) CO 77 Mylan Receives Approval 77 Crofelemer budesonide foam 77 Phase 2a Trial 77 Phase III Trial 77 Phase IIa Clinical Trial 77 Submits Application 77 Preclinical Data 77 Nasdaq XTLB 77 Initiate Phase II 77 Announces Publication 77 MKC# MT 77 Vaccine Adjuvant 77 Multiple Ascending Dose 77 Announces Licensing Agreement 77 initiated Phase Ib 77 Develop Novel 77 Announces License Agreement 77 Awarded Qualifying Therapeutic 77 Announce Merger Agreement 77 Transdermal Patch 77 GVAX ® 77 Trial Evaluating 77 Commences Phase III 77 dependent kinase inhibitor 77 Receives Tentative Approval 77 Inc Therapeutic Competitors 76 Patients Treated With 76 non nucleoside inhibitor 76 NDA Submission 76 Vitrasert R 76 Investigational Treatment 76 Kinase Inhibitor 76 Study Evaluating 76 pharmacogenomic translational research 76 Teva Provides Update 76 Receives NASDAQ 76 Launches Generic Version 76 FDA Okays 76 Nasdaq VNDA 76 Announce Licensing Agreement 76 platform HDL Mimetic 76 Vascular Disrupting Agent 76 First Patient Dosed 76 Personalized Immunotherapy 76 Files Shelf Registration Statement 76 Tezampanel 76 Abstract Accepted 76 Inc. www.micromet inc.com 76 Antitumor Activity 76 Announces Presentation 76 Phase 2a Clinical Trial 76 AAG geldanamycin analog 76 Pivotal Study 76 Amends Agreement 76 acetonide FA 76 XL# anticancer compounds 76 Protease Inhibitor 75 TRACON Pharmaceuticals 75 Demonstrates Potential 75 candidates Azedra TM 75 TELINTRA R 75 Inc. Nasdaq OXGN 75 novel emulsion formulation 75 FDA Approvals 75 Announces Dosing 75 Prolongs Survival 75 oral prodrug 75 Cites Positive 75 FDA APPROVES 75 Begins Shipment 75 Humanized Anti 75 Randomized Phase 75 Reacquires 75 Oral Fingolimod 75 Severe Sepsis 75 Completes Patient Enrolment 75 RNAi Therapeutic 75 Randomized Phase II 75 Shows Promise Against 75 Clinical Trial Evaluating 75 Aeolus Pharmaceuticals Announces 75 IND Application 75 Telik logo TELINTRA 75 please visit http:/www.vandapharma.com 75 Antibody Drug Conjugate 75 Pivotal Trial 75 Vicriviroc 75 Pegloticase 75 TKB# 75 Genentech Wyeth Pharmaceuticals 75 Announces Successful Completion 75 Receives SFDA Approval 75 Taro Receives 75 Drug Shows Promise 75 ATRA IV 75 Announces Positive 75 Receives Favorable 75 Collaborators Publish 75 Pharma Merck Serono 75 Files Patent Application 75 R roscovitine CDK cyclin 75 Genentech sanofi aventis 75 Receives CE Marking 75 hypoxia activated prodrug 75 Reports Positive 75 proprietary intranasal insulin 75 developing Zerenex ferric 74 visit http:/www.mannkindcorp.com 74 developing ACAPODENE 74 Submits Investigational 74 Sign License Agreement 74 Shows Promising 74 Veronate R 74 Lupus Drug 74 Improves Survival 74 Spectrum Pharmaceuticals Announces 74 Phase 1b Clinical Trial 74 oncolytic virus therapies 74 markets COLAZAL 74 Confirmatory Phase 74 anti botulism antibody 74 Namenda Memantine HCl 74 TM Aganocide 74 Merck Serono Nycomed 74 Boehringer Ingelheim MedImmune 74 Pafuramidine 74 Novel Antibiotic 74 Receives Patent 74 Milestone Payment 74 Dose Ranging Study 74 Expand Collaboration 74 pan histone deacetylase 74 Receives Conditional 74 markets HP Acthar 74 Phase #b/#a clinical 74 oral nucleoside analogue 74 Nasdaq MNKD focused 74 lead molecular radiotherapeutic 74 TRANSDUR ® 74 recurrent metastatic ovarian cancer 74 Fast Track Status 74 CysDisplay R 74 Therapeutic Competitors Report 74 Lung Cancer Drug 74 Orally Active 74 VentiRx Pharmaceuticals 74 vapreotide acetate 74 Nasdaq MNKD focuses 74 Single Dose 74 palonosetron hydrochloride Injection Dacogen 74 TO AVOID PREGNANCY WHILE 74 Exherin 74 Nasdaq EPCT 74 Romidepsin 74 Taglich Brothers Initiates Coverage 74 Signs License Agreement 74 INSPIRE Trial Phase III 74 markets Testim ® 74 FDA Approves 74 Sinks Lower 74 essential thrombocythemia ET 74 Obtains License 74 AUDIO PROVIDED BY 74 please visit http:/www.atherogenics.com 74 agonistic human 74 Immunomedics Announces 74 methylnaltrexone bromide 74 SPRYCEL ® 74 Mg Usa 74 developing Bicifadine serotonin 74 Acquires Exclusive 74 HDAC Inhibitor 74 Provides Update Regarding 74 visit www.genenews.com 74 Preclinical Study 73 Confirms Efficacy 73 Metastatic Melanoma 73 Advanced Melanoma 73 Agonist MABA program 73 Pruvel TM 73 Nasdaq PGNX 73 MKC# 73 Achieves Milestone 73 MKC# MKC# PP 73 product platforms AZX# 73 Gout Drug 73 candidate XP# 73 Pooled Analysis 73 Receives Positive Opinion 73 TRANSDUR ™ 73 MOVIPREP R 73 Novartis Novo Nordisk 73 Anti Tumor 73 evaluating picoplatin 73 Patent Covering 73 Significantly Improves 73 lintuzumab SGN 73 Shows Promise 73 Merck OSI Pharmaceuticals 73 lexidronam injection 73 HCV RNA polymerase 73 Sapacitabine 73 MEK Inhibitor 73 MBRX 73 First Patient Treated 73 Nasdaq HALO 73 RNAi Therapeutics 73 Extends Collaboration 73 ARRY # 73 CYT# potent vascular disrupting 73 IND Filing 73 molecular imaging radiopharmaceutical 73 Small Molecule 73 virus HCV protease inhibitor 73 PHRM 73 includes TOLAMBA TM 73 Shows Statistically Significant 73 Aflibercept 73 Tyrosine Kinase Inhibitor 73 Voluntarily Withdraw 73 telomerase therapeutic 73 Regains NASDAQ 73 Matrix Phase 2b 73 Arthritis Drug 73 RANK Ligand inhibitor 73 LymphoStat B TM 73 Biopharmaceuticals AG 73 visit www.sciclone.com 73 Generic Version 73 Selective Electrochemical Tumor Ablation 73 PNP inhibitor 73 Rheumatoid Arthritis Drug 73 Migraine Drug 73 By JENNIFER LEARN 73 Milestone Payment From 73 HuMax TAC 73 R lenalidomide 73 SPL# Gel vaginal microbicide 73 Aradigm Logo 73 Identifies Potential 73 orally administered inhibitor 73 Prostate Cancer Vaccine 73 drug pipeline TAFA# 73 OTC BB PVCT 73 Commercialize Novel 73 JAK Inhibitor 73 proprietary intravenous formulation 73 HGS ETR1 mapatumumab 73 Begins Clinical Trial 73 KRYSTEXXA TM pegloticase 73 programs visit http:/www.bionovo.com 73 Jumps Higher 73 Develops Novel 73 Adjunctive Therapy 73 Patent Issued 73 Colaris Colaris AP 73 Biogen Genentech 73 albiglutide 73 estrogen receptor beta agonist 73 REG1 Anticoagulation System 73 diarrhea fatigue asthenia 73 Successfully Completes Tender Offer 73 gets USFDA nod 73 Obtains Approval 73 initiated Phase 1b 73 Aztreonam Lysine 73 CHEAP ONLINE PHARMACY LOW 73 CD# CEA 73 Investigational Drug 73 evaluating bafetinib 73 Atripla combines 73 candidate deforolimus 73 Elagolix 73 R Saizen R 73 Refractory Hodgkin Lymphoma 73 Safinamide 73 4SC AG ISIN DE# 73 Demonstrates Sustained 72 Second Pivotal Phase 72 CCR5 mAb 72 includes Dideco CarboMedics 72 selective immunoproteasome inhibitor 72 Maribavir 72 BIOTECHNOLOGY SOURCE 72 Receives Positive 72 Restructures Operations 72 vinorelbine tartrate 72 novel proprietary KL4 72 Obtains Exclusive License 72 Vitrasert ® 72 Successfully Treats 72 Pharmaceuticals Initiates 72 Complicated Skin 72 humanized therapeutic 72 Epilepsy Drug 72 Demonstrates Efficacy 72 IMPDH inhibitor 72 website www.celsion.com 72 Previously Treated 72 MSCRAMM ® 72 novel VDA molecule 72 Invites Investors 72 ALN HPN 72 hyaluronidase enzyme 72 Study Demonstrates 72 delivers fluocinolone acetonide FA 72 Therapeutic Competitors 72 Adjuvant Treatment 72 LymphoStat B belimumab 72 II Clinical Trial 72 Luveris R Ovidrel R 72 XL# XL# 72 toenail onychomycosis 72 Inc. OTCBB ECTE 72 NASDAQ MNKD focuses 72 Initiated Phase 72 Paris IPN Euronext 72 Sangamo BioSciences Announces 72 Settle Patent Litigation 72 2 methoxyestradiol 72 induced macular edema 72 Patient Enrolment 72 evaluating satraplatin 72 Trastuzumab DM1 72 Recombinant Human 72 Friedreich Ataxia FRDA 72 COLAZAL R 72 Cholesterol Lowering Drug 72 Oral Formulation 72 Corp. AMEX CVM 72 Randomized Double Blind 72 AVI BioPharma Announces 72 markets XIFAXAN ® 72 Nasdaq AVNC 72 Announces Issuance 72 Q1 Loss Narrows 72 Corp. NASDAQ CYTR 72 novel orally inhaled 72 Myriad logo BRACAnalysis 72 AFREZZA TM 72 selectin antagonist 72 Immunotherapeutic 72 please visit http:/www.sunesis.com 72 highly purified pasteurized 72 Nasdaq PARD 72 Psoriasis Drug 72 Shows Efficacy 72 Welcomes Analyst Initiation 72 ALTROPANE R 72 Genentech GlaxoSmithKline 72 refractory chronic lymphocytic 72 Announces Favorable 72 developing Surfactant Replacement 72 Vascular Inflammation 72 ELADUR ™ 72 Terminate Merger Agreement 72 Novartis Organon 72 Monoclonal Antibody 72 Chronic Hepatitis C 72 successfully commercialize Iluvien 72 Bazedoxifene 72 MCSP respectively 72 Expands Scientific Advisory 72 highly selective inhibitor 72 orally inhaled migraine 72 Ridaforolimus 72 Receives Clearance 72 topical gel formulation 72 mGluR2 positive 72 Therapeutic Vaccine 72 Completes Initial 72 Nicotine Conjugate Vaccine 72 Dose Ranging 72 Regains Full 72 2 inhibitor CYT# 72 peptidic compound 72 www.ucb group.com 72 Exercises Option 72 KAI Pharmaceuticals 72 Signs Merger Agreement 72 OTCBB PYTO 72 kidney urologic 72 Signs Licensing Agreement 72 signal detection CTSD 72 Alvine Pharmaceuticals 72 Diabetic Neuropathy 72 Announces Stockholder Approval 72 evaluating mipomersen 72 Potelligent Technology 72 visit www.targanta.com 72 IMiDs ® 72 Therapeutic Antibody 72 Licenses Patents 72 Completes Merger With 72 please visit www.medicinova.com 72 MONSTERSTOX.COM Monsterstox.com 72 SABER ™ 72 Randomized Double blind 72 personalized cellular immunotherapy 72 Secures Financing 72 P#X# antagonist 72 ADP receptor antagonist 72 NicVAX TM 72 interferon gamma 1b 72 Amigal TM 72 Receives Regulatory 72 Study Showed 72 Nasdaq ACHN 72 sarcoma melanoma 72 Enters Into Collaboration 72 DARA logo 72 PEGylated Fab fragment 72 Tibotec BVBA 72 SIX RO ROG 72 TRIOLEX ™ 72 Clinical Study Shows 72 Announces Immediate Availability 72 ELADUR TM 71 induced mucositis 71 Preclinical Models 71 molecular therapeutics immunotherapies 71 adecatumumab MT# 71 Phase 2b Study 71 RELOVAIR ™ 71 Issued Patent 71 Board Authorizes 71 Diabetic Foot Ulcer 71 VEGFR2 inhibitor 71 Vidaza R 71 candidate AQ4N 71 Phase Ib IIa 71 VIVUS Announces 71 ASE SVA 71 Empatic ™ 71 Inhalation Aerosol 71 Improves Outcomes 71 Schizophrenia Drug 71 Grants Orphan Drug 71 Alnylam Nasdaq ALNY 71 Orally administered 71 investigational oral inhibitor 71 website http:/www.celsion.com 71 Tramiprosate ALZHEMED TM 71 Oral Insulin Capsule 71 Inc. NASDAQ SIRT 71 By JAMAAL ABDUL 71 FOLFOX6 chemotherapy regimen 71 oral picoplatin 71 oral ghrelin agonist 71 Alfacell proprietary ribonuclease 71 Lenocta TM 71 subsidiaries visit http:/www.apricusbio.com 71 Catalyst Biosciences 71 COLAZAL ® 71 Phase III multicenter 71 Unanimously Recommends Approval 71 Ovitrelle R Serostim 71 Nasdaq AEGR 71 lead Aganocide compound 71 Board Unanimously Rejects 71 human IgG1 monoclonal 71 Announce Collaboration 71 Telaprevir VX 71 Multicenter Randomized 71 Inc. ProMetic www.prometic.com 71 Announces Dismissal 71 Kosan dependence 71 Signs Option Agreement 71 Demonstrates Potent 71 personalized dendritic 71 Vitamin D analogue 71 Aloxi ® 71 PHX# 71 evaluating tivozanib 71 Treatment Naïve 71 AMEX KAL 71 sapropterin dihydrochloride 71 Wins Patent Infringement 71 5 HT3 antagonist 71 OTCBB IMUC 71 Archexin 71 Brentuximab Vedotin SGN 71 Nasdaq DVAX 71 Albuferon TM 71 combines bupropion 71 Begin Clinical Trials 71 Hormone Refractory Prostate Cancer 71 Flamel Technologies Announces 71 cytomegalovirus immune globulin 71 novel synthetic PEGylated 71 Polymerase Inhibitor 71 Vertex Pharmaceuticals Announces 71 HCV Protease Inhibitor 71 OTCBB FCSC 71 Q3 Loss Widens 71 Ceflatonin R 71 Q2 Loss Narrows 71 Testosterone MDTS ® 71 developing Zerenex TM 71 compound INCB# 71 interferon beta 1a infertility 71 Milestone Payments 71 Staphylococcus aureus Immune Globulin 71 Awarded Patent 71 topical antifungal product 71 PANVAC VF 71 Aganocide 71 Secures Additional 71 Anticancer Agent 71 Multicenter Phase 71 Zorbtive TM 71 Inc. Nasdaq IMGN 71 Receives Favorable Ruling 71 Transcept Pharmaceuticals 71 brand ciclesonide HFA 71 OTCBB GNTA 71 Retains CCG Investor Relations 71 EVIZON TM 71 SAR# [002] 71 please visit www.abraxane.com 71 http:/www.sunesis.com 71 compound ISA# 71 proprietary radiolabeled monoclonal 71 Tech DVAX 71 THERAPEUTICS 71 Q3 Loss Narrows 71 Settle Patent Dispute 71 targeted radiotherapeutic 71 derivatives Radilex TM 71 Announces Effective Date 71 particularly SANCTURA XR 71 ABLYNX 71 Takeda Kyowa Hakko Kirin 71 please visit http:/www.supergen.com 71 Plaque Psoriasis 71 NASDAQ ENMD 71 Nasdaq IMGN 71 oropharyngeal candidiasis OPC 71 Anti CD# Antibody 71 TSX CTI 71 Introduces Novel 71 OTCQB CTIX 71 Romiplostim 71 Nasdaq ONXX 71 Sagent Pharmaceuticals Announces 71 rusalatide acetate 71 balsalazide disodium Capsules 71 GATTEX TM 71 approved incretin mimetic 71 Pancreas Cancer Vaccine 71 Nicotine Vaccine 71 Early Relapsing Multiple 71 Closes Previously Announced 71 Pivotal Clinical Trial 71 including eniluracil ADH 71 Obtains FDA 71 developing adecatumumab 71 Oral Laquinimod 71 Prodarsan R 71 Pivotal Phase II 71 GTC NASDAQ GTCB 71 NRGN 71 Wafer polifeprosan 71 5 lipoxygenase activating 71 ALN PCS 71 ® bortezomib 71 Anticancer Compound 71 Peginterferon alfa 2b 71 OTCBB HNAB 71 Omacetaxine 71 telomerase inhibitor drug 71 5q MDS 71 Vaccine Candidate 71 intranasal formulation 71 Completes Financing 71 PDX pralatrexate 71 Expanded Indication 71 Regains Compliance With 71 compound PMX # 71 delivery polymer matrix 71 Valortim TM 71 sanofi aventis Bayer Schering 71 treat chronic sinusitis 71 Bradmer Pharmaceuticals 71 product candidate Lpathomab 71 memantine HCl 71 Molecular Diagnostic Test 71 Genotyping Test 71 IL# PE#QQR 71 Liprotamase 71 oral proteasome inhibitor 71 dextromethorphan quinidine 71 Biomarker Study 71 INDICATED LOWER 71 Aloprim TM allopurinol sodium 71 Exploit collaboration 71 Cetrorelix 71 IgG1 monoclonal antibody 71 PROVENGE ® 71 Acute Attacks 71 Advancing Drugs 71 Dose Escalation 71 ThermoDox ® clinical 71 Effectively Treats 71 visit http:/www.PAREXEL.com 71 systemic juvenile idiopathic 71 Closes Second Tranche 71 NASDAQ VPHM 71 Hematology Molecular Pathology 70 topically applied SEPA 70 Vidaza ® 70 targeted anticancer biopharmaceuticals 70 Fentanyl Patch 70 Announces Postponement 70 Eluting Stent 70 Phase Ib II 70 Phase 2a Study 70 nasal decolonization 70 Receives Tentative FDA 70 Pivotal Trials 70 Xeloda ® 70 Supplemental Biologics License Application 70 BayStreet.ca Research Alert 70 Reports Receipt 70 Nasdaq CTIC 70 PI3K/Akt pathway inhibitor 70 Successfully Completes Acquisition 70 PRESENTED AT 70 visit www.stemcellthera.com 70 Hedgehog Pathway Inhibitor 70 Oral Insulin 70 platinum chemotherapeutic 70 Announces Termination 70 NASDAQ ADLR 70 Mg Uk 70 apricitabine ATC 70 docetaxel Taxotere R 70 Pulmonary Arterial Hypertension 70 label Lipofen R 70 NeutroPhase TM 70 CybeRelease Decliners 70 Iluvien ® 70 Slows Progression 70 PF # [002] 70 HuCAL PLATINUM R 70 Osteoporosis Drug 70 Attracting Bullish Investors 70 ® adefovir dipivoxil 70 Successfully Treated 70 CYP#A# CYP#D# 70 Intravenous Human 70 M# rationally 70 Prochymal TM 70 NASH Huntington 70 Solazed TM 70 Syncria R 70 Commercialize 70 multicenter Phase III 70 Bullish Average Crossover 70 Dyax logo 70 ThermoDox R 70 OTCBB IGXT 70 dasatinib Sprycel ® 70 Awarded Patents 70 Demonstrates Ability 70 Prospective Randomized 70 Q2 Loss Widens 70 Namenda ® 70 Diamyd Medical Diamyd 70 pentadentate logo R 70 investigational humanized monoclonal antibody 70 Phase III Trials 70 erlotinib Tarceva R 70 dihydrochloride Tablets 70 submitted Biologics License 70 rasagiline tablets 70 Kuvan R 70 cell carcinoma RCC 70 corticotropin injection 70 Cypher Sirolimus 70 WeissComm Partners +#-#-#-# 70 Regains Compliance 70 Sign Definitive Merger 70 5 FU leucovorin 70 NYSE Amex YMI 70 visit http:/www.neogenomics.org 70 Successfully Closes 70 Provides Shareholder 70 Nasdaq TARG 70 Report companiesandmarkets.com adds 70 NOTE POSIDUR ™ 70 Oracea TM 70 selective A2A adenosine receptor 70 Spiegelmer ® 70 Gets Bearish Confirmation 70 Cutaneous T 70 Shareholders Approve Acquisition 70 technology visit http:/www.genmab.com 70 nasal calcitonin product 70 mertansine 70 Oral Suspension USP 70 Announce Early Termination 70 DP VPA 70 NYSE Amex PBTH 70 candidate REP# 70 IIa Clinical Trial 70 Amex PTN 70 S. Arzerra 70 Well Tolerated 70 Announces Cancellation 70 Anidulafungin 70 Dose Finding 70 ABL inhibitor 70 candidates Azedra 70 Successfully Concludes 70 Bullish Technical Alert 70 Rigel R# 70 Seliciclib CYC# 70 progressive metastatic prostate 70 Disease Modifying 70 GENR 70 Hematological Malignancies 70 VISICOL R 70 Announces Commencement 70 Telik Announces 70 Inc. Nasdaq MITI 70 products MKC# PP 70 Extend Collaboration 70 Deforolimus 70 OTCBB OHRP 70 Vaccine Protects Against 70 Serostim ® 70 Updates Status 70 accumulate preferentially 70 NASDAQ AVNR 70 Settles Litigation 70 Am J Obstet 70 Voluntarily Withdraws 70 Adenoviral 70 Lupus Nephritis 70 Predictive medicine 70 Strengthens Position 70 OTCBB QTXB 70 Novel Compound 70 Patients Enrolled 70 SinuNase TM 70 J Am Coll 70 Demonstrates Long Term 70 Provectus Pharmaceuticals specializes 70 AMEX RGN 70 TSX Delisting Review 70 pan HDAC inhibitor 70 factor TNF receptor 70 Announce Definitive Agreement 70 Nitazoxanide 70 Receptor Agonist 70 Rotavirus Vaccine 70 Bosutinib 70 AllPennyStocks.com Spotlights 70 PEGylated docetaxel 70 Inc. OTCBB ALRX 70 GVAX R 70 STERIS Corporation Announces 70 Successfully Completes 70 ® lenalidomide 70 novel MetAP 2 70 Blood Pressure Drug 70 Parathyroid Hormone 70 AKT inhibitor 70 Inc. NASDAQ QLTI 70 Significantly Reduces 70 Preclinical Efficacy 70 Glufosfamide 70 Corp. www.anavex.com 70 Microplasmin 70 HuCAL GOLD R 70 R famotidine 70 Nasdaq OSIP 70 Phase Ib Clinical Trial 70 GlaxoSmithKline MedImmune 70 CCX# B 70 OTCStockExchange.com Stock Alert 70 Ltd. OTCBB IMUC 70 Locteron exclusively 70 Inc. NASDAQ VSGN 70 AN# topical anti 70 antibody MAb 70 Strengthens Balance Sheet 70 Potent Antiviral Activity 70 Horizant ™ 70 www.ucb.com 70 PHASE III 70 Entry Inhibitor 70 Recurrent Glioblastoma 70 Disease IBD 70 small molecule glucokinase 70 Announces Adjournment 70 OTCBB DORB 70 Introduce Next Generation 70 pipeline ImmunoGen collaborators 70 Frozen Shoulder syndrome Adhesive 70 Nasal Powder 70 trastuzumab Herceptin R 70 VIVITROL ® 70 NewsBite Downgrade Puts Pressure 70 please visit www.dyax.com 70 Combination Treatment 70 Patients Receiving 70 TRIOLEX HE# APOPTONE HE# 70 diarrhea predominant irritable 70 R memantine HCl 70 ODT metoclopramide HCl PEPCID 70 Demonstrates Statistically Significant 70 Ostarine ™ 70 Completes Previously Announced 70 CD4 monoclonal antibody 70 monoclonal antibody IgG1 Mab 70 novel histone deacetylase 70 StaphVAX R 70 familial amyloidotic polyneuropathy FAP 70 Q4 Loss Widens 70 HuCAL PLATINUM ® CysDisplay 70 Ecallantide 70 Palifosfamide 70 please visit www.sucampo.com 70 Anticancer Drug 70 researches develops licenses 70 5 fluorouracil leucovorin 70 Inc. OTCBB CAXG 70 Bucindolol 70 MAGE A3 ASCI 70 Novel Therapeutic 70 metaglidasen 70 OMNARIS HFA 70 Diabetic Nephropathy 70 Silodosin 70 developing ostarine selective 70 phase III isavuconazole 70 Cholesterol Drug 70 Inks Licensing Deal 70 Onyx Pharmaceuticals Announces 70 Subsidiary Enters 70 Appoints Seasoned 70 Nasdaq NPSP 70 Phase IIa Trial 70 XIAFLEX ® 70 Company website www.anormed.com 70 Finalizes Acquisition 70 Cerebril TM 70 Announce Commencement 70 Tesetaxel 70 TNF Tumor Necrosis Factor 70 Panzem R 70 Efficacy Results 70 Double Blind Placebo 70 cancer neuroendocrine tumor 70 Topline Results 70 oral beclomethasone dipropionate 70 Announce Expiration 70 Efficacy Trial 70 Neulasta R 70 Civacir 70 Antithrombin 70 rxRNA 70 Consummates 70 humanized monoclonal 70 Nasdaq IDIX 70 Gentamicin Surgical Implant 70 Mutually Agree 70 Emtriva Viread 70 Testosterone MDTS R 70 Levoleucovorin 70 Announces Underwriters Exercise 70 PEGylated anti 69 website http:/www.sinovac.com 69 novel antimitotic agent 69 Inks MOU 69 SUTENT ® 69 GNSZ 69 Patients Treated 69 oral renin inhibitor 69 Nasdaq CYCC 69 Anti Tumor Activity 69 catheter occlusion 69 Naive Patients 69 VYVANSE TM lisdexamfetamine 69 DURECT proprietary 69 Maven Semantic 69 RealPennies.com RealPennies.com 69 KSP inhibitor 69 motexafin gadolinium Injection 69 mesylate tablets approved 69 Glatiramer Acetate 69 Cypress Bioscience Inc 69 IN PATIENTS WITH 69 Nasdaq CLDX 69 BCG refractory carcinoma 69 Bearish Average Crossover 69 oral Janus kinase 69 NASDAQ XTLB 69 novel therapeutic antibodies 69 Heart Transplant Recipients 69 Factor Receptor 69 Successfully Completed 69 Million Milestone Payment 69 hypereosinophilic syndrome 69 GTC recombinant form 69 immunosuppressive compound 69 Relapsed Refractory

Back to home page